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Abstract 
Background: Residual phenylalanine hydroxylase (PAH) activity is the key determinant for 
the phenotype severity in phenylketonuria (PKU) patients and correlates with the patient’s 
genotype. Activity of in vitro expressed mutant PAH may predict the patient's phenotype and 
response to tetrahydrobiopterin (BH4), the cofactor of PAH. 
Methods: A robust LC-ESI-MSMS PAH assay for the quantification of phenylalanine and 
tyrosine was developed. We measured PAH activity a) of the PAH mutations p.Y417C, 
p.I65T, p.R261Q, p.E280A, p.R158Q, p.R408W, and p.E390G expressed in eukaryotic COS-
1 cells; b) in different cell lines (e.g. Huh-7, Hep3B); and c) in liver, brain, and kidney tissue 
from wild-type and PKU mice.  
Results: The PAH assay was linear for phenylalanine and tyrosine (r2 ≥0.99), with a 
detection limit of 105 nmol/L for Phe and 398 nmol/L for Tyr. Intra-assay and inter-assay 
coefficient of variation was < 5.3% and < 6.2%, respectively, for the p.R158Q variant in lower 
tyrosine range, respectively. Recovery of tyrosine was 100%. Compared to the wild-type 
enzyme, the highest PAH activity at standard conditions (1 mmol/L L-Phe; 200 mol/L BH4) 
was found for the mutant p.Y417C (76%), followed by p.E390G (54%), p.R261Q (43%), 
p.I65T (33%), p.E280A (15%), p.R158Q (5%), and p.R408W (2%). A relative high PAH 
activity was found in kidney (33% of the liver activity), but none in brain.  
Conclusions: This novel method is highly sensitive, specific, reproducible, and efficient, 
allowing the quantification of PAH activity in different cells or tissue extracts using minimum 
amounts of samples under standardized conditions.  
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Introduction 
Deficiency of phenylalanine hydroxylase (PAH, EC 1.14.16.1) is causing 
phenylketonuria (PKU, OMIM 261600), an autosomal recessively inherited disease 
presenting with elevated blood phenylalanine (Phe) levels [1, 2]. The phenotypic severity of 
PKU is characterized by the type of mutation, and thus by residual PAH enzyme activity. The 
fully functional homotetrameric PAH catalyzes hydroxylation of Phe to tyrosine (Tyr) in the 
presence of cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) and molecular oxygen 
[3, 4]. According to the Locus Knowledgebase (PAHdb, www.pahdb.mcgill.ca), about 60% of 
mutations in the PAH gene are missense mutations, which may lead to a misfolding of the 
protein [5, 6], disturbing the complex enzyme regulation and changes in kinetics, due to 
altered affinities for the Phe substrate and the BH4 cofactor. 
The incidence of PKU is about 1 in 10’000 newborns in Caucasian populations [2]. 
For most patients, therapy consists in a life-long dietary restriction of Phe to prevent 
neurological impairment. Recently, it has been reported that a subgroup of PKU patients 
(mild to moderate phenotype) can benefit from a pharmacological therapy with BH4 
(sapropterin dihydrochloride; Kuvan®) [7, 8]. Newborn screening program for PKU, initially 
based on the Guthrie test [9], has been established for the early detection of PKU patients. 
Today, electrospray tandem mass-spectrometry (ESI-MSMS or TMS) is the method of choice 
for fast screening and monitoring of Phe and Tyr levels in dried blood spots (DBS) [10]. 
Of the over 550 disease-causing mutations listed in the PAHdb [11], 88 were 
expressed in different in vitro cell systems to estimate the residual PAH activity. Expression 
systems like Escherichia coli, eukaryotic cell lines, or cell-free systems were most commonly 
used systems [12-14]. In addition to cell systems, PAH activity was studied in rat liver biopsy 
samples [15]. Expression of recombinant PAH in bacteria was applied for characterization of 
physical and chemical properties of the enzyme [16].  
Previous methods for PAH activity measurement were based on the determination of 
14C-labelled Tyr produced [3] or release of 3H [17]. Other methods are based on detection of 
Tyr by fluorescence [18], colorimetric assays [19], or fluorescence monitoring [20]. Recently 
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described method by Gersting et al. [20] was developed for characterization of purified 
mutant PAH proteins at different Phe and BH4 concentrations.  
In our novel assay, we applied liquid chromatography (LC) ESI-MSMS for the 
quantification of Tyr produced from Phe. Prior to analysis, the amino acids are derivatized to 
propyl chloroformate derivatives, using the commercially available Phenomenex EZ:faastTM 
kit. Our method allows for short analysis times and higher limit of detection and is optimized 
for determination of PAH enzyme activity of recombinantly expressed mutant proteins in 
COS-1 and other cell lines, as well as in mice liver, kidney, and brain. Thus, it allows 
comparison between different mutant proteins at standard conditions. 
 
Materials and Methods 
Materials 
The Phenomenex EZ:faastTM kit for LC ESI-MSMS amino acid analysis was 
purchased from Phenomenex (Torrance, CA, USA). L-phenylalanine-d5 and L-tyrosine-d4 
standard reagents were purchased from Cambridge Isotope Laboratories, Inc. (Andover, MA, 
USA) whereas L-phenylalanine-d8 was obtained from C/D/N Isotopes Inc. (Pointe Claire, 
Quebec, Canada). L-Phenylalanine and L-tyrosine, as well as the DMEM cell culture medium 
were purchased from Sigma Aldrich (St. Louis, MO, USA). RPMI 1640 medium was from 
Invitrogen (San Diego, CA, USA). BH4 dihydrochloride was obtained from Schircks 
Laboratories (Jona, Switzerland). Mouse tissues were extracted from C57BL/6 (wild-type) or 
C57Bl/6-Pahenu2 (PKU) [21] mice strains. 
 
Expression plasmid preparation 
The expression plasmid pCMV-FLAG-PAH (Promoter-N-Fusion-PAH) was received 
as courtesy gift from L.R. Desviat [22]. Mutations in the human PAH-cDNA sequence were 
introduced by site-directed mutagenesis, using QuikChange XL kit from Agilent Technologies 
(Santa Clara, CA, USA) and confirmed by sequencing analysis using BigDye Terminator 
Cycle sequencing v1.1 (Applied Biosystems) on an ABI Prism 3100 Sequencer. 
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Transfection of cells and preparation of mouse tissue 
Cell lines (COS-1, Hep3B, HuH-7) were cultured either in DMEM or RPMI1640 
(HaCat, lymphoblasts) medium, with appropriate additives, at 37°C under 5% CO2. One day 
prior to transfection, COS-1 cells were seeded at 2x105 cells/ml in 10-cm dishes. 
Transfection experiments were performed using Fugene 6 (Roche Diagnostics, Mannheim, 
Germany) according to manufacturer’s recommendations. Hereby, 13 μg of the pCMV-
FLAG-PAH plasmid (either wild-type or mutant) were co-transfected with 2 μg of pSV-βgal 
reporter plasmid (Promega, Madison, USA). Transfected cells were harvested after 48 hours 
for determination of PAH activity or flash-frozen in liquid N2 for storage at -80°C.  
Transfection efficiency was verified by determining β-galactosidase activity in 5 μl 
lysate in PAH assay cell lysis buffer (1xPBS pH 7.4, 0.25 M sucrose, Complete protease 
inhibitors cocktail (Roche)) using in-situ β-galactosidase enzyme assay system (Promega, 
Madison, USA). PAH activities of wild-type and mutants were normalized according to 
transfection efficiency.  
Frozen mouse tissues were lysed in homogenization buffer (10 μl/mg tissue), as 
described in [23], and homogenized using Qiagen TissueLyser II at 4 °C. After centrifugation 
at 13’000g and 4°C for 30 min, supernatants were kept frozen at -80°C. 
 
PAH activity assay 
Cell lysates were prepared and enzyme activity was determined using previously 
described methods [24]. Briefly, assay conditions included pre-incubation at 25°C with L-Phe 
(1 mmol/L) for 4 minutes, then Fe(NH4)2(SO4)2 (100 µmol/L) was added, and incubation was 
continued for one more minute. After 5 minutes total pre-incubation time, BH4 (200 μmol/L for 
cell extracts or 75 μmol/L for mouse tissue) was added to start the reaction. Between 2.5 and 
20 μl (2-165 μg) of total protein lysate extracted from cells or mouse tissue were used for 
activity measurements. The applied total protein amount depended on lysate type, 
transfected, non-transfected, or mouse tissue samples. It was generally higher for sample 
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types with low activity where only little amounts of Tyr were produced. Initially, this was 
determined empirically by measuring a series of increasing total protein amounts for each 
sample type to determine the measurable linear range. Reaction time was 2 minutes for 
mouse tissue lysates and 15 minutes for cell lysates. Short incubation time reduces any 
possible chaperone-like effect of BH4. The amount of Tyr produced was determined by LC 
ESI-MSMS (see below). 
Protein concentrations of all sample types were determined using Pyrogallol Red 
protein dye binding assay [25] after completion of PAH assay due to low stability of protein 
lysates. Specific PAH activities are expressed in mU per mg total protein to account for 
differences in total protein amount and with mU equal to nmol L-Tyr produced per minute.  
 
Stock solution preparation and calibration 
Labeled internal standard stock solutions (10 mmol/L Phe-d5 or 10 mmol/L Tyr-d4) 
were prepared in 50 mmol/L HCl, stored at -20°C, and freshly diluted to working 
concentrations (see sample preparation). Stock solutions of non-labeled Phe (50 mmol/L) 
and Tyr (8 mmol/L) were prepared for calibration curves in 50 mmol/L HCl and stored at -
20°C.  
Working solutions for calibration curves were freshly prepared from the non-labeled 
stock solutions in H2O from 100 to 700 μmol/L Phe and 4 to 350 μmol/L Tyr (Table 1). In 
order to include the matrix effect to the calibration curves, 20 μl of COS-1 non-transfected 
cell lysate was added to the calibration samples.  
 
Sample preparation and derivatization 
 Samples were prepared according to the Phenomenex EZ:faastTM kit’s manual [26], 
with the following modifications: prior to amino acid extraction and derivatization, 20 μL of 
each internal standard solution containing 100 μmol/LPhe-d5 and 20 μmol/L Tyr-d4 (in 50 
mmol/L HCl) were added to 20 μL of sample lysate. Using the kit’s reagents, the amino acids 
are derivatized with propyl chloroformate resulting in the addition of a propyl formate group, 
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and a propyl group at the amine group, and the carboxylic group of the amino acids, 
respectively.  The hydroxy group of Tyr is also derivatized by the addition of a propyl formate 
group. 
 
Instrumentation 
For RP (reversed phase)-HPLC separation of amino acids, a 250 x 2 mm C18 column 
(Phenomenex EZ:faastTM) was used. The derivatized amino acids were separated using the 
following program: (i) isocratic flow 75% solvent B for 6 min; (ii) linear gradient from 75% to 
95% solvent B (v/v) in 9 min; (iii) linear gradient from 95% to 100% solvent B in 0.1 min; (iv) 
isocratic flow 100% solvent B for 3 min;  (v) linear gradient from 100% to 75% solvent B in 
0.1 min; (vi) isocratic flow 75% solvent B for 2 min. Solvents A and B were 10 mmol/L 
ammonium formate in H2O and 10 nmol/L ammonium formate in methanol, respectively. 
Flow rate was 150 μL/min, and the injection volume was 10 μL. 
A PerkinElmer SCIEX API 2000 LC-ESI-MSMS system equipped with a PerkinElmer 
Series 200 autosampler and two PerkinElmer Series 200 micro pumps were used for LC-ESI 
MSMS analysis. Amino acids were acquired using the multiple reaction mode (MRM) positive 
ion mode, with the following transitions: 294 → 206 (Phe), 299 → 211 (Phe-d5), 302→214  
(Phe-d8), 396 → 308 (Tyr), and 400 → 312 (Tyr-d4), 403 → 315 (Tyr-d7). The dwell time was 
500 ms. Mass spectra were acquired in the time range of 6 to 20 minutes. 
 
Immunoquantification by Western Blot 
Five to 50 µg of lysate from activity assay was used for verifying PAH expression in 
the various cell lines or mouse tissue samples by Western blotting, using commercially 
available anti-PAH antibody PH8 (Abcam, Cambridge, UK) and donkey anti-goat IgG-HRP 
(Santa Cruz Biotechnology, CA, USA). Antibody binding was detected by enhanced 
chemiluminescence (Amersham ECLTM) as described by the manufacturer’s instructions (GE 
Healthcare, CT, USA). 
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Limit of detection 
The limit of detection (LOD) was determined by measuring six blank samples of non-
transfected COS-1 cell lysate with very low amounts of Phe and Tyr using the following 
formula:  
LOD = ((mean + 3.3) * standard deviation) / slope  
The limit of quantification (LOQ) for Phe and Tyr was calculated as follows:  
LOQ = ((mean + 10) * standard deviation) / slope 
 
Results 
Linearity and limit of detection 
Figure 1 depicts linear regression of calibration standards for Phe and Tyr. Both 
calibration curves are linear with correlation coefficients of r2≥0.99. 
The LOD was 105 nmol/L for Phe and 398 nmol/L for Tyr and LOQ 147 nmol/L for 
Phe and 574 nmol/L for Tyr.  
 
Imprecision and recovery 
Inter- and intra-assay analyses were performed with the wild-type enzyme, with 
medium activity (p.R261Q), and low activity (p.R158Q) PAH variants, transfected into COS-1 
cells. Six samples were each prepared either on the same day (intra-assay) or during the 
period of two weeks (inter-assay). Table 2 summarizes the intra- and inter-assay imprecision 
measurements of the method. 
The intra-assay coefficient of variation (CV) varied between 2.4% and 10.8% and 
between 2.7% and 8.9% for Tyr and Phe, respectively (Table 2). The inter-assay imprecision 
data for Tyr and Phe ranges from 5.3% to 14.3% (Table 2). Comparable CVs in the intra- and 
inter-assays show that the PAH assay samples are stable over more than 2 weeks at -20°C.  
The recovery of 100 μmol/L exogenous Tyr added to the variant PAH p.R261Q after 
PAH assay was 100% (data not shown).  
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Analytical performance 
Three characteristic parameters, retention time, mother ion mass, and daughter ion 
mass were measured in the LC-ESI-MSMS method for each analyte, e.g. 12.59 min, m/z 396 
Da and m/z 308 for Tyr. Figure 2a shows a representative chromatogram of a wild-type PAH 
assay sample with the peak-pairs at 11.0 minutes representing Phe (294206) and IS-Phe 
(299211) and at 12.6 minutes assigned to Tyr (396308) and IS-Tyr (400312). The 
peaks at 9.0 and 12.2 minutes correspond to d3-methionine and homophenylalanine and are 
the internal standards included in the Phenomenex EZ:faastTM kit.  
 
PAH activity assay 
The linearity of the PAH enzyme assay was investigated using transfected COS-1 
cells with human wild-type PAH. The reaction time was optimized to 15 minutes. As 
demonstrated in Figure 2b, Tyr production increased linearly with the amount of protein. 
However, the linear range of assay is rather small (< 250 mol/L) and PAH activity decreases 
with increasing Tyr production, due to reagent availability in the reaction mixture and possible 
product inhibition. All mutants produced lower amounts of Tyr at similar reaction times, 
compared with the wild-type enzyme. Stability of PAH during the reaction is critical and short 
reaction time should be used at low protein concentrations (< 30 g for the wild-type PAH 
and <165 g for low-activity mutants). 
The wild-type PAH activity in COS-1 cells was 43.9 ± 14.5 mU/mg protein under 
standard reaction conditions (15 minutes reaction time and 5 µl cell lysate). PAH intra-assay 
variation determined in triplicate was 7.3%, 6.4%, and 7.5% for the wild-type, p.R261Q and 
p.I65T in COS-1 cells, respectively.  
Comparative analyses of activity for wild-type PAH activity in transfected COS-1 cells 
using a HPLC-based assay with fluorimetric detection [27] provided similar values of activity 
for wild-type (38 ± 2 mU/mg) and R261Q mutant (16 ± 1 mU/mg). However, this HPLC based 
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analysis requires > 30 µg of protein in each assay, i.e. 1.5-6 fold higher than in the LC-ESI- 
LC-ESI-MSMS assay at the selected conditions. 
PAH mutations found in PKU patients 
In order to further evaluate the LC-ESI-MSMS method, we determined PAH activity of 
several known PAH mutations, in addition to p.R261Q and p.R158Q used in the method 
characterization and development (see above). Figure 3a shows the percent of PAH mutant 
activities compared to the wild-type activity for the I65T (33%), R261Q (43%), R158Q (5%), 
R408W (2%) and E390G (54%) proteins.  
These mutations have previously been tested in different in vitro systems, but we also 
analyzed two novel PAH mutations p.E280A and p.Y417C, recently reported in Turkish PKU 
patients [28] (Figure 3a). While a severe p.E280A mutation exhibits only 15% of the wild-type 
PAH activity, a mild p.Y417C mutation was almost as active as the wild-type enzyme (76%). 
All mutant PAH activities were normalized for β-galactosidase, which was co-transfected into 
COS-1 cells.  
Figure 3b illustrates the different PAH mutant proteins by Western blot analysis. All of 
the PAH mutant proteins with rather low activity also present with reduced amounts of PAH 
protein, when compared to the wild-type (Figure 3c). The only exception is p.R158Q with a 
very low activity and substantial amount of protein. PAH expression was normalized for β-
actin expression in these COS-1 cells and quantified by densitometry.  
 
PAH activity in mouse tissue  
The quantification of PAH activity with the novel LC-ESI-MSMS method is not only 
restricted to cell extracts, but can also be used for animal tissues. For this purpose, we 
measured PAH activity in liver, kidney, and brain tissue from wild-type (C57BL/6) or PKU 
mice (C57Bl/6-Pahenu2).  
Figure 4a shows PAH activity in liver, kidney and brain extracts from the wild-type and 
PKU mice. As expected, the highest activity was found in liver of the wild-type mouse. A 
relatively high PAH activity (33% of the liver) was found in the kidney, whereas in tissues 
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from the PKU mice no PAH activity was detectable. No PAH activity was observed in brain 
extracts from the wild-type animals.  
The Western blot analysis shows high amounts of PAH protein in the wild-type mice 
extracts from liver and kidney, while in the same organs of the PKU mice bands of the PAH 
protein were detected despite no activity (Figure 4b). These results correlate well with the 
enzyme activity measurements for the wild-type mouse (Figure 4a). The PAH expression 
seems to appear as two signals in Western blot analysis. This double bond of PAH has 
previously been observed for PAH in tissues, when expressed in eukaryote systems, and 
was found to be the result of an apparent electrophoretic shift of the Ser-16 phosphorylated 
enzyme [4]. 
 
PAH activity in different cell lines 
For in vitro PAH expression studies, liver or kidney mammalian cells (organs with 
highest PAH activity) exhibit the most similar physiological environment. However, these cell 
lines might exhibit endogenous PAH activity that interfere with activity from transfected PAH. 
Therefore, we investigated PAH expression and PAH activity in several common hepatic cell 
lines (e.g. HepG2, Hep3B and HuH-7) (Figure 5a). No PAH activity or protein was detected 
in HepG2 cells, and only low endogenous activity was found in Hep3B and HuH-7 cells 
(Figures 5a and 5b). 
Using the labeled Phe-d8 isotope in the PAH assay, which is consequently oxidized to 
Tyr-d7, we were able to distinguish the assay product Tyr-d7 from Tyr from the cell extracts. 
We found that PAH activities using Phe-d8 are lower than using non-labeled Phe (32.5 
mU/mg versus 43.7 mU/mg protein) due to a possible isotope effect, but high enough to 
discriminate between different PAH mutants. The same reduction accounts for the p.R261Q 
mutant, but the activity of this mutant is consistently measured to be 40% of wild-type PAH 
activity both with Phe or Phe-d8 as substrates. 
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Figure 5b shows wild-type PAH protein expression in Hep3B, HuH-7, and COS-1 
cells, compared to non-transfected cells. No wild-type PAH protein could be detected from 
non-transfected Hep3B, HuH-7, and COS-1 cell lines with 20 μg of total protein analyzed.   
Furthermore, no PAH activity or protein was detected in EBV-transformed 
lymphocytes, even though PAH transcript can be amplified from their RNA [29]. Also, no 
PAH activity and transcript could be detected in the HaCat cell line (human adult low calcium 
high temperature keratinocytes).  
 
Discussion 
Molecular mechanisms of PKU and other hyperphenylalaninemias were established 
over several decades through investigations of mutations within the PAH gene [30]. Based on 
genotype findings and description of BH4-responsive forms of PKU [31], functional assays of 
mutation effects in vitro have proven to be very fruitful for the characterization of PAH 
mutations, building a bridge between patient and pure protein. Although, these data sets tend 
to overestimate PAH activities in vivo. Residual in vitro PAH activity was shown to correlate 
with the patient’s phenotype [32]. Thus, knowing patient’s residual PAH activity can be 
relevant for selecting therapeutic options, the likely Phe tolerance, and the expected 
response to BH4 [28]. 
In this study, we have developed a new method for the quantification of the amino 
acids Phe and Tyr by LC ESI-MSMS, as a basis for the measurement of PAH activity. The 
EZ:faastTM sample preparation (amino acid extraction, washing and derivatization steps are 
included in the procedure) was originally developed for the rapid processing and measuring 
of biological fluids in clinical analyses. We optimized this procedure to the quantitative 
determination of PAH activity in an in vitro expression system and in various mouse tissues. 
Using the EZ:faastTM kit, sample preparation is fast and time consuming steps, such as 
protein precipitation, removal of interfering substances (e.g. salts and other buffer 
components), or elaborating derivatization procedures, can be omitted. Furthermore, since 
our mass spectrometric analysis technique enables the application of isotopically labeled 
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internal standards (Phe-d5 and Phe-d8, Tyr-d4), our method is highly specific and reliable. It is 
suitable for the quantification of Phe and Tyr even in very complex biological matrices. Its 
fast and simple sample preparation procedure allows for the analysis of a big sample series 
in a short amount of time. 
The calibration range of Phe and Tyr is variable and can be selected according to the 
type of in vitro expression system and predicted enzyme activity. Low coefficients of variation 
in intra- and inter-assay confirm that the method can be applied in the nanomolar range.  
The PAH assay method used for the quantification by MS is a discontinuous assay 
commonly used in PAH mutation studies. The time between extraction of total protein from 
cultured cells and enzymatic reaction is critical and should be kept short. Our expression 
system in COS-1 cells shows a high transfection efficiency and protein expression, therefore 
only little amounts of total protein are required for assessing activity. We verified this method, 
to determine activities in the linear range and diluted the proteins accordingly. Thus, other 
systems with lower protein expression can be easily quantified by this new method. 
Every PAH mutant was assessed in at least three different transfection systems and 
quantification experiments. The results of each mutant, expressed as percent of wild-type 
PAH, are well in accordance with previously published data for the same mutations [33]. The 
slight differences found were due to the fact that previously reported PAH activity 
measurements were performed under different assay conditions and using several 
substrates with different affinities (e.g. BH4, 6-methyl-tetrahydropterin or 6,7-dimethyl-
tetrahydropterin) [3, 12]. In previous reports, in vitro activities for some mutations (e.g. 
p.R261Q) ranged between 24 – 100%, depending on the expressions system and assay 
used [34, 35]. 
Two new PKU mutations, p.E280A and p.Y417C, are described in our study, which 
were detected among a larger Turkish patients cohort and were not previously expressed in 
vitro. The activities determined for p.E280A and p.Y417C mutants (15% and 76% of the wild-
type PAH) correlate with the severity of hyperphenylalaninemia in the corresponding 
patients.  
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The quantification of Phe and Tyr is not only limited to cell extracts, but can also be 
used on various mouse tissues. The advantages of using Phenomenex EZ:faastTM kit also 
apply to these complex biological samples, omitting interferences from the mixtures. Thus, 
the liver is not the only site of PAH expression in humans and animals. Up to 40% PAH 
activity has been reported in the kidneys, as compared to the liver in human tissue [36]. In 
this study, we report 33% of kidney PAH activity in wild-type mouse tissue in relation to PAH 
activity in liver, in accordance with previous data in rodents [37]. In addition to liver and 
kidneys, significant PAH activity and expressions were also reported in pancreas tissue [36, 
38]. Keratinocytes were suggested as potential target for PKU gene therapy [39] and claimed 
to contain intact PAH metabolism [40], however with our assay no PAH activity or protein was 
detected in these cells.  
In contrast to the method published by Gersting et al. [20], our method measures 
PAH activity at standardized Phe and BH4 concentrations and may be a good screening 
method for selection of mutations of interest for the kinetic studies at different Phe and BH4 
concentrations [41]. Thus, the main application of this new method will be the quantification of 
the relative in vitro PAH activity in patients with PKU by expressing mutant proteins in COS-1 
cells. A recent study with a large cohort of Turkish PKU patients suggested that both the 
phenotype and BH4-responsiveness are genotype-dependent and that the residual PAH 
activity is a good predictor for the severity of the disease [28]. Finally, this method can easily 
be extended to other amino acids since labeled compounds are available as internal 
standards for quantification.  
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Legend to Figures 
 
Figure 1: Calibration curves (linear regression) for Phe and Tyr using Phe-d5 and Tyr-d4 as 
internal standards for quantification. The ratio of analyte peak area and corresponding 
internal standard are plotted as a function of analyte concentration.  
 
Figure 2: (a) Mass spectrum of wild-type PAH expressed in COS-1 cells, prepared with 
EZ:faast kit and measured by LC ESI-MSMS. Preparation by the kit includes 3 additional 
internal standards to correct for sample preparation variability. These are d3-methionine, 
homophenylalanine and homoarginine (not shown in the spectrum below); (b) Linearity of Tyr 
production from PAH wild-type expressed in COS-1 cells transfected with increasing 
amounts of plasmid. 
 
Figure 3: (a) PAH activities of various common PAH mutant proteins expressed in COS-1 
cells and quantified by LC-ESI-MSMS. Activities are displayed as % wt activity. All PAH 
activities are normalized with β-galactosidase activity for correction of transfection efficiency. 
(b) Western blot analysis of wild-type PAH and mutations tested for PAH activity. The same 
amount of total protein (25 μg) was analyzed per lane. (c) PAH expression in all samples 
was normalized with β-actin expression and expressed as % wild-type PAH expression. Non-
transfected COS-1 cells do not show PAH protein. 
 
Figure 4: (a) Comparison of absolute PAH activity in mouse tissues of wild-type (C57BL/6) 
and PKU (C57Bl/6-Pahenu2) mice (n = 3). Standard deviation results for PKU liver and brain 
are not displayed due to very small values. (b) Western blot analysis of PAH expression in 
liver (L), kidney (K) and brain (B) tissue from wild-type and PKU mice. As shown by β-actin 
loading control, increased protein amounts of brain tissue were loaded.  
 
Figure 5: (a) PAH activity in various cell lines, eventually for use as cell host in in vitro 
studies or previously analyzed in PAH metabolism. (b) Western blot analysis of protein 
 21 
lysates from various cell lines transfected with wild-type PAH probed for PAH expression. 
20μg of total protein analyzed (5 μg of COS-1 wild-type due to high expression), NT=non-
transfected 
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Table 1: Standards used for the calibration curve of L-Tyr and L-Phe.  
STANDARD 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
[Tyr] µmol/L 0 4 8 12 16 20 40 60 80 100 150 200 250 350 
[Phe] µmol/L 0 50 100 150 200 250 300 350 400 450 500 550 600 700 
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Table 2: Imprecision data of Phe and Tyr quantification determined with wild-type, R261Q 
and R158Q PAH samples. The intra- and inter-assays were performed with individual cell 
lysates (n=6). All PAH activities are normalized by co-transfection with pSV-βgal. 
 
1
CV = coefficient of variation 
2
Varying reactions conditions: 30 min reaction time and 24.5µg total protein in inter-assay compared 
to 15 min reaction time and 9.0 µg total protein in intra-assay experiment 
 
  
 
 Wt PAH p.R261Q p.R158Q 
 Mean (SD) 
µmol/L 
CV
1
 (%) Mean (SD) 
µmol/L 
CV
1
 (%) Mean (SD) 
µmol/L 
CV
1
 (%) 
Intra-assay (n=6)       
Phe 417.3 (37.2) 8.92 339.8 (9.1) 2.68 436.4 (28.9) 6.63 
Tyr 83.2 (9.0) 10.81 142.2 (3.4) 2.38 7.7 (0.5) 6.16 
Inter-assay (n=6)       
Phe 321.5 (18.5) 5.75 414.9 (48.5) 11.68 520.1 (45.0) 8.66 
Tyr 210.4 (25.5) 12.13 125.6 (17.9) 14.29 14.9 (0.9) 5.28 
PAH Activity 
(mU/mg protein) 
   
Intra-assay (n=6) 61.4
 
16.6 2.34 
Inter-assay (n=6) 28.5
2 
20.8 2.71 
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
